outbreak
sever
acut
respiratori
syndrom
sar
caus
sarsassoci
coronaviru
involv
countri
patient
result
death
thereaft
sar
reemerg
sporad
laboratori
commun
set
clinic
spectrum
vari
minim
respiratori
symptom
sever
respiratori
failur
previous
contribut
overview
contemporari
treatment
sar
whole
topic
also
review
elsewher
articl
aim
focu
manag
subgroup
critic
ill
sar
patient
signific
respiratori
failur
critic
ill
sar
patient
frequent
demonstr
follow
clinic
featur
persist
pyrexia
occasion
admiss
often
recur
initi
period
defervesc
tachycardia
infrequ
bradycardia
tachypnoea
signific
oxygen
desatur
onethird
sar
patient
requir
high
flow
oxygen
therapi
requir
intens
care
unit
icu
admiss
high
depend
care
develop
acut
respiratori
distress
syndrom
ard
clinic
cours
patient
progress
relentlessli
irrespect
attempt
pharmacolog
treatment
eventu
result
septic
shock
andor
multipl
organ
dysfunct
syndrom
mod
lymphocytopaenia
neutrophilia
thrombocytopenia
frequent
seen
critic
ill
sar
patient
neutrophilia
could
due
sar
per
se
superimpos
infect
relat
corticosteroid
administr
pancytopaenia
present
could
due
haemophagocytosi
syndrom
reactiv
latent
human
parvoviru
unpublish
data
prolong
activ
partial
thromboplastin
time
pictur
dissemin
intravascular
coagul
report
coinfect
agent
includ
chlamydialik
agent
metapneumoviru
influenza
viru
unpublish
data
report
persist
increas
elev
creatin
kinas
lactat
dehydrogenas
transaminas
level
common
associ
lung
damag
believ
result
virallytrigg
inflammatori
reaction
mediat
host
cytokin
sicker
patient
level
proinflammatori
cytokin
higher
slower
declin
clinic
recoveri
radiograph
abnorm
chest
usual
progress
upward
initi
unilater
bilater
lowerto
midzon
peripher
groundglass
shadow
focal
multifoc
diffus
consolid
peak
radiograph
chang
occur
day
fever
onset
show
two
peak
day
show
relentless
progress
cavit
rare
may
associ
superimpos
infect
patient
prolong
ill
cours
mechan
ventil
highresolut
comput
tomographi
hrct
thorax
show
focal
groundglass
scatter
crazi
pave
pattern
present
follow
develop
interstiti
thicken
consolid
pleural
reaction
scar
fibrosi
later
stage
small
cm
pulmonari
cyst
may
detect
even
patient
receiv
ventilatori
assist
subcutan
emphysema
pneumothorac
pneumomediastinum
distinct
complic
sever
sar
hrct
featur
latestag
ard
caus
sar
similar
aris
caus
lung
biopsi
postmortem
studi
show
acutephas
diffus
alveolar
damag
dad
airspac
edema
bronchiolar
fibrin
increas
number
interstiti
macrophag
focal
haemophagocytosi
alveolar
macrophag
patient
shorter
durat
day
ill
hand
histolog
ill
show
organizingphas
dad
increas
fibrosi
hyperplasia
type
ii
pneumocyt
squamou
metaplasia
multinucl
giant
cell
acut
bronchopneumonia
patient
die
late
cours
diseas
high
load
viral
rna
detect
revers
transcriptas
polymeras
chain
reaction
rtpcr
lung
bowel
lymph
node
spleen
liver
kidney
gener
principl
antibacteri
therapi
communityacquir
pneumonia
accord
standard
guidelin
alway
administ
laboratori
confirm
sarscov
infect
effect
antivir
therapi
avail
start
earli
possibl
diagnosi
even
empir
suspici
clinic
featur
especi
epidemiolog
link
present
sinc
critic
ill
patient
deem
alreadi
progress
viral
replic
phase
immunopatholog
phase
concomit
institut
immunomodulatori
therapi
also
consid
sinc
consensu
regard
optim
treatment
regimen
respect
thu
review
commonli
use
agent
discuss
rel
merit
base
publish
report
respiratori
failur
eventu
set
oxygen
supplement
assist
ventil
intens
support
treatment
requir
ribavirin
commonli
use
empir
antivir
agent
sar
broadspectrum
purin
nucleosid
analogu
inhibit
rna
dna
virus
interf
nucleic
acid
synthesi
experiment
evid
show
immunomodulatori
effect
treatment
mous
coronaviru
hepat
subsequ
found
ribavirin
direct
vitro
activ
sarscov
higher
dose
given
intraven
result
frequent
sever
advers
effect
includ
haemolyt
anaemia
elev
transaminas
level
bradycardia
lopinavirritonavir
coformul
kaletra
abbott
laboratori
usa
proteas
inhibitor
treatment
human
immunodefici
viru
hiv
infect
inhibit
coronavir
proteas
thu
block
process
viral
replicas
polyprotein
prevent
replic
viral
rna
ritonavir
inhibit
lopinavir
metabol
thu
increas
serum
concentr
activ
sarscov
retrospect
analysi
hong
kong
patient
receiv
kaletra
rescu
therapi
togeth
high
dose
corticosteroid
differ
rate
oxygen
desatur
intub
mortal
compar
match
cohort
howev
given
initi
treatment
combin
ribavirin
anoth
subgroup
patient
signific
reduct
need
rescu
puls
corticosteroid
therapi
intub
rate
overal
mortal
addit
preval
diarrhoea
among
patient
may
render
oral
drug
appropri
use
synerg
kaletra
ribavirin
might
contribut
benefit
sinc
either
drug
alon
weak
antivir
activ
anoth
hong
kong
studi
sar
patient
treat
combin
lopinavirritonavir
ribavirin
compar
patient
histor
control
treat
ribavirin
show
advers
clinic
outcom
ard
death
significantli
lower
treatment
group
histor
control
day
symptom
onset
randomis
placebo
control
trial
requir
interferon
famili
cytokin
import
role
cellular
immun
respons
interferon
use
sar
treatment
china
canada
openlabel
uncontrol
studi
nine
patient
treat
corticosteroid
plu
interferon
infergen
intermun
inc
usa
show
better
oxygen
satur
faster
radiograph
resolut
lesser
need
supplement
oxygen
compar
given
corticosteroid
alon
vitro
test
show
interferon
potent
interferon
effect
even
administ
sarscov
infect
cell
cultur
tradit
chines
herbal
medicin
use
concomitantli
drug
treat
sar
mainland
china
good
result
report
howev
valu
critic
ill
patient
report
glycyrrhizin
activ
compon
deriv
liquoric
root
effect
sarscov
vitro
clinic
util
remain
uncertain
anoth
herbal
compound
baicalin
also
demonstr
antisarscov
activ
vitro
unpublish
data
absenc
effect
antivir
agent
outbreak
physician
opt
use
immunomodulatori
agent
commonli
corticosteroid
treatment
sar
gener
agre
corticosteroid
use
earli
viral
replic
phase
administr
best
coincid
onset
immunopatholog
phase
clinicoradiolog
surrog
criteria
use
indic
onset
immun
hyperact
phase
thu
provid
practic
guid
time
start
corticosteroid
corticosteroid
dosag
high
enough
especi
sever
case
abort
cytokin
storm
maintain
long
enough
prevent
rebound
phenomenon
may
achiev
use
weightadjust
radiograph
extentmodifi
dosag
period
week
onethird
half
sar
patient
fever
may
recur
immunomodulatori
treatment
due
superimpos
infect
rapid
tail
corticosteroid
persist
sever
uninhibit
cytokin
storm
empir
antipseudomon
antibiot
given
first
appar
clinic
respons
opportunist
infect
like
fungal
infect
exclud
fever
accompani
obviou
respiratori
deterior
absenc
superimpos
pulmonari
system
infect
patient
presum
suffer
sever
recrudesc
sar
ill
critic
ill
sar
patient
escal
immunomodul
warrant
deterior
could
sometim
occur
rapidli
immedi
administr
puls
methylprednisolon
therapi
mg
per
day
intraven
day
follow
taper
dose
subsequ
week
associ
improv
outcom
onethird
onehalf
critic
ill
sar
patient
may
benefit
strategi
radiograph
abnorm
may
lag
behind
clinic
improv
persist
radiograph
shadow
per
se
accompani
clinic
improv
warrant
addit
corticosteroid
human
gamma
immunoglobulin
use
select
sar
patient
continu
deterior
despit
treatment
igmenrich
immunoglobulin
product
pentaglobin
biotest
pharma
gmbh
germani
use
hong
kong
mainland
china
pentaglobin
three
day
given
patient
deterior
despit
repeat
rescu
methylprednisolon
ribavirin
therapi
shown
improv
radiograph
score
oxygen
requir
report
use
combin
methylprednisolon
highdos
intraven
immunoglobulin
daili
three
consecut
day
probabl
sar
patient
acut
lung
injuri
ali
ard
result
lower
mortal
trend
toward
earlier
recoveri
random
control
trial
larger
number
patient
requir
confirm
efficaci
base
assumpt
neutral
immunoglobulin
convalesc
plasma
curb
increas
viral
load
convalesc
plasma
collect
recov
sar
patient
use
hong
kong
treat
sever
ill
patient
respond
corticosteroid
clinic
benefit
reportedli
observ
small
number
patient
despit
effort
least
sar
patient
would
still
develop
acut
hypoxem
respiratori
failur
requir
supplement
oxygen
overal
patient
admit
icu
eventu
requir
intub
mechan
ventil
noninvas
invas
ventilatori
support
appli
critic
ill
sar
patient
niv
deliv
continu
posit
airway
pressur
cpap
bilevel
pressur
support
tightfit
facial
nasal
mask
commonli
employ
mani
chines
hospit
centr
hong
kong
earli
applic
may
benefici
could
rapidli
improv
vital
sign
oxygen
tachypnoea
may
reduc
need
increas
dosag
corticosteroid
progress
respiratori
failur
could
avoid
intub
invas
ventil
twothird
critic
ill
sar
patient
use
niv
immunocompromis
subject
diseas
report
similarli
reduc
rate
endotrach
intub
seriou
complic
niv
sar
may
particular
benefit
sinc
high
dose
corticosteroid
per
se
would
alreadi
predispos
ventilatorassoci
pneumonia
risk
healthcar
worker
hcw
could
also
markedli
reduc
obviat
need
intub
potenti
highli
infecti
procedur
patient
respond
niv
usual
within
hour
nonrespond
eventu
need
endotrach
intub
thu
identifi
earli
niv
indic
presenc
ali
earli
ard
oxygen
satur
spo
could
improv
despit
litr
per
minut
oxygen
persist
tachypnoea
least
breath
per
minut
progress
radiograph
deterior
lung
usual
contraind
niv
appli
includ
impair
conscious
uncoop
patient
high
aspir
risk
haemodynam
instabl
sarsrel
respiratori
failur
respond
readili
niv
given
low
pressur
cpap
cm
h
bilevel
pressur
support
inspiratori
posit
airway
pressur
ipap
cm
h
expiratori
posit
airway
pressur
epap
cm
h
reason
start
pressur
higher
pressur
avoid
whenev
possibl
may
increas
risk
pneumothorax
pneumomediastinum
frequent
spontan
complic
sar
even
without
assist
posit
pressur
ventil
patient
improv
within
one
two
day
niv
continu
deterior
niv
contraind
endotrach
intub
mechan
ventil
consid
centr
adopt
ventilatori
strategi
similar
recommend
ard
caus
pressur
volum
control
ventil
may
employ
tidal
volum
kept
low
eg
mlkg
predict
bodi
weight
plateau
pressur
maintain
cm
h
higher
risk
barotrauma
sar
lowest
posit
endexpiratori
pressur
peep
could
achiev
satisfactori
alveolar
recruit
oxygen
usual
cm
water
employ
adjunct
measur
employ
usual
ard
case
tri
sar
includ
prone
posit
high
frequenc
oscillatori
ventil
nitric
oxid
high
peep
regular
lung
recruit
efficaci
uncertain
tracheostomi
requir
patient
requir
prolong
mechan
ventil
icu
stay
strict
adher
infect
control
guidelin
mandatori
perform
tracheostomi
icu
oper
room
well
subsequ
chang
tracheostomi
tube
critic
ill
sar
patient
high
dose
corticosteroid
mechan
ventil
particularli
suscept
superimpos
bacteri
opportunist
infect
peripher
blood
also
lower
normal
ventilatorassoci
infect
organ
like
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
acinetobact
baumanii
well
invas
mucor
sp
aspergillosi
report
strict
control
hyperglycaemia
corticosteroid
administr
essenti
reduc
chanc
septic
complic
spontan
subcutan
emphysema
pneumothorac
pneumomediastinum
common
complic
potenti
aggrav
noninvas
invas
ventil
chest
drain
insert
use
reliev
pneumothorac
prolong
air
leak
may
sometim
occur
sar
predominantli
result
singl
organ
failur
lung
complic
report
like
result
sepsi
attend
problem
includ
acut
renal
failur
acut
liver
failur
rhadomyolysi
cardiovascular
dysfunct
prolong
immobil
underli
comorbid
includ
deep
vein
thrombosi
pulmonari
embol
ischaem
stroke
etc
casefat
ratio
cfr
sar
estim
rang
depend
age
group
affect
overal
cfr
approxim
variabl
may
due
differ
host
viral
factor
well
treatment
strategi
cfr
may
also
significantli
affect
durat
followup
inclus
differ
mix
suspect
probabl
laboratori
confirm
case
differ
seri
base
treatment
principl
present
develop
standard
treatment
protocol
earli
outbreak
compris
initi
high
puls
dose
methylprednisolon
taper
three
week
protocol
eventu
appli
consecut
admit
sar
patient
mean
age
year
laboratoryconfirm
sar
low
overal
mortal
obtain
three
death
occur
patient
age
year
twenti
four
percent
requir
icu
admiss
receiv
niv
bilevel
pressur
support
alon
niv
invas
mechan
ventil
hrct
thorax
survivor
taken
day
commenc
treatment
show
clinic
signific
lung
scar
anoth
multicent
studi
compar
four
treatment
regimen
guangzhou
china
also
found
regimen
high
dose
corticosteroid
adjust
accord
clinic
radiolog
sever
coupl
nasal
cpap
ventil
produc
best
result
zero
mortal
clinicallydefin
sar
patient
mean
age
year
treat
cpap
none
requir
mechan
ventil
subsequ
low
mortal
record
among
patient
treat
regimen
mani
prognost
factor
report
independ
predict
advers
outcom
sar
includ
advanc
age
diabet
heart
diseas
signific
coexist
condit
short
breath
admiss
degre
hypoxaemia
high
total
leukocyt
count
admiss
high
initi
lactat
dehydrogenas
low
platelet
count
use
puls
dose
corticosteroid
compar
patient
nasopharyng
aspir
neg
sarscov
rtpcr
pcrposit
one
like
requir
icu
care
mechan
ventil
develop
acut
renal
failur
die
particular
mortal
high
among
icu
patient
icu
mortal
various
report
older
age
sever
ill
lymphocyt
count
decreas
steroid
dose
posit
fluid
balanc
chronic
diseas
immunosuppress
nosocomi
sepsi
associ
poor
icu
outcom
patient
diarrhoea
like
requir
ventilatori
support
icu
care
higher
serum
sarscov
concentr
earli
stage
diseas
prognost
indic
later
icu
admiss
patient
present
extens
radiograph
involv
also
predict
need
icu
care
death
age
alon
consist
strong
prognost
factor
seri
agestratifi
death
rate
estim
patient
year
age
year
year
elderli
patient
year
old
correspond
estim
hong
kong
year
age
year
caus
death
sar
usual
progress
respiratori
failur
without
concomit
sepsi
sudden
cardiac
arrest
also
possibl
hypothes
due
hypoxemia
would
worsen
activ
includ
defaec
direct
viral
myocardi
injuri
extrem
anxieti
may
lead
electr
instabl
myocardium
induct
arrhythmia
sar
primarili
transmit
direct
indirect
contact
mucou
membran
eye
nose
mouth
infecti
respiratori
droplet
fomit
transmiss
risk
increas
durat
proxim
contact
infect
control
precaut
icu
shown
appendix
endotrach
intub
consid
earlier
anticip
impend
deterior
ampl
time
avail
prepar
perform
skil
airway
practition
negativepressur
room
behind
close
door
oper
choos
wear
addit
person
protect
equip
like
airmat
hepa
power
air
purifi
respir
system
mn
usa
hesh
must
familiar
mode
oper
precaut
requir
gown
degown
must
assist
colleagu
similar
knowledg
modifi
awak
intub
techniqu
suggest
best
possibl
compromis
patient
oper
safeti
administr
combin
midazolam
fentanyl
lidocain
patient
reach
desir
level
sedat
patient
paralys
intub
minim
cough
altern
rapid
sequenc
induct
techniqu
intraven
administr
midazolam
suxamethonium
also
minim
patient
cough
howev
emphas
unless
prior
prepar
surgic
airway
neuromuscular
paralysi
avoid
anticip
difficult
intub
order
maintain
spontan
respir
bronchoscopi
niv
perform
neg
pressur
room
although
widespread
fear
infect
risk
niv
centr
experi
includ
found
use
safe
necessari
precaut
taken
final
strict
adher
infect
control
measur
form
strict
isol
effect
cohort
earli
diagnosi
contact
trace
time
report
institut
public
health
measur
well
enhanc
environment
ventil
key
compon
effect
manag
infecti
diseas
manag
critic
ill
sar
patient
challeng
task
knowledg
clinic
aspect
sar
base
retrospect
observ
data
randomizedcontrol
trial
requir
confirm
physician
scientist
world
collabor
studi
condit
may
potenti
threaten
human
exist
